Included in the formulation
АТХ:A.05.A.A.01 Chenodeoxycholic acid
Pharmacodynamics:Being a physiological bile acid system of the hepatic-intestinal circulation, replenishes the pool of conjugated bile acids, reducing the relative amount of dioxygen and trioxycholic bile acids and increasing the concentration of phospholipids. As a result, the synthesis of cholesterol in the liver is inhibited, which leads to a decrease in its concentration in the bile. By increasing the solubility of cholesterol, the lithogenic index of bile is reduced, partial or complete dissolution of cholesterol stones in the ducts and gall bladder occurs.
Pharmacokinetics:After oral administration, it is completely absorbed in the gastrointestinal tract. In the liver it is conjugated with amino acids, after which it is secreted into bile and again excreted into the intestine.
Elimination with feces.
Indications:It is used in the detection of cholesteric gallstones in the gallbladder of no more than 20 mm with the preserved function of the gallbladder and the full patency of the vesicle and common bile duct.
XI.K80-K87.K80 Gallstone disease [cholelithiasis]
Contraindications:Calcified gallstones, bowel dysfunction, malabsorption syndrome,cholic colic, acute inflammatory diseases of the gallbladder, bile ducts, pancreas, ulcerative colitis, inflammatory diseases of the gastrointestinal tract, peptic ulcer of the stomach and duodenum in the acute phase, chronic hepatitis, cirrhosis, hepatic and renal failure, individual intolerance, child age to 18 years.
Carefully:Hypersensitivity.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Inside, at 15 mg / kg per day. The course of treatment: from 3 months to 2-3 years.
The highest daily dose: 1.5 g.
Side effects:Nausea, pain in the epigastric region, biliary colic, increased serum transaminase levels, diarrhea, allergic reactions: itching and skin rashes.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:Enhances the effect of hypoglycemic agents.
Decrease efficiency colestramine, colestipol and containing aluminum antacids, because they bind chenodeoxycholic acid in the intestine.
Special instructions:After successful treatment in patients with a pronounced predisposition to cholelithiasis, it is recommended for preventive maintenance every third month to take the drug at 250 mg per day during the first month.
If the application is ineffective for 6 months, further use of chenodeoxycholic acid it is inappropriate.